The U.S. FDA Approved Oyster Point Pharma Inc Product TYRVAYA™ to Treat Dry Eye Disease

Oyster Point Pharma, Inc. 

The U.S. Food and Drug Administration (FDA) has approved the Oyster Point Pharma Inc (OYST) product TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg for the treatment of signs and symptoms of dry eye disease.

TYRVAYA™ Nasal Spray

TYRVAYA Nasal Spray is the first and only nasal spray approved for the treatment of dry eye disease.

TYRVAYA Nasal Spray is believed to bind to cholinergic receptors to activate the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease. Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases.

Leave a Reply